Informações:
Falhas:
ID
34167
Descrição
Cardiotoxicity of Adjuvant Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT00858039
Link
https://clinicaltrials.gov/show/NCT00858039
Palavras-chave
Versões (1)
- 14/01/2019 14/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
14 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Neoplasms NCT00858039
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
female 18 years or older
boolean
ID.2
Item
histologically confirmed, completely excised invasive breast cancer with her-2 overexpression
boolean
ID.3
Item
primary surgery less than twelve weeks prior to registration
boolean
ID.4
Item
lvef>50% as assessed by transthoracic echocardiogram or gated heart pool scan
boolean
ID.5
Item
eastern cooperative oncology group performance status 0-2
boolean
ID.6
Item
adjuvant systemic treatment plan comprises at least three cycles of anthracycline chemotherapy and 52 weeks of trastuzumab
boolean
ID.7
Item
before patient registration, informed consent must be given according to local regulations.
boolean
ID.8
Item
pregnancy
boolean
ID.9
Item
distant metastases from breast cancer
boolean
ID.10
Item
any systemic chemotherapy prior to study entry
boolean